Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Terheyden, Patrick
KEYNOTE-D18, NCT05155254 / 2021-004594-32: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)	Active, not recruiting	3	407	Europe, US, RoW	IO102-IO103, Pembrolizumab	IO Biotech, Syneos Health, Merck Sharp & Dohme LLC	Metastatic Melanoma, Unresectable Melanoma	07/25	09/27
TRIM, NCT05750511: Multicenter Tissue Registry in Melanoma	Recruiting	N/A	1000	Europe	molecular tissue analysis	Dermatologic Cooperative Oncology Group	Metastatic Melanoma	02/24	02/25
NCT03683550: Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma	Active, not recruiting	N/A	836	Europe	SLNE with preoperative hybrid SPECT/CT, Standard SLNE	University Hospital, Essen	Melanoma	06/25	06/25
Kahle, Birgit
No trials found